Revance Therapeutics, Inc. (RVNC): Price and Financial Metrics


Revance Therapeutics, Inc. (RVNC): $33.13

-0.75 (-2.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RVNC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RVNC POWR Grades

  • Growth is the dimension where RVNC ranks best; there it ranks ahead of 59.11% of US stocks.
  • The strongest trend for RVNC is in Growth, which has been heading down over the past 177 days.
  • RVNC ranks lowest in Stability; there it ranks in the 3rd percentile.

RVNC Stock Summary

  • With a price/sales ratio of 25.67, REVANCE THERAPEUTICS INC has a higher such ratio than 94.8% of stocks in our set.
  • RVNC's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 91.31% of US stocks.
  • Revenue growth over the past 12 months for REVANCE THERAPEUTICS INC comes in at 72.42%, a number that bests 88.23% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to REVANCE THERAPEUTICS INC are NTRA, LNSR, OCX, VMEO, and DMRC.
  • RVNC's SEC filings can be seen here. And to visit REVANCE THERAPEUTICS INC's official web site, go to www.revance.com.

RVNC Valuation Summary

  • In comparison to the median Healthcare stock, RVNC's price/sales ratio is 370.59% higher, now standing at 24.
  • RVNC's price/sales ratio has moved down 710.5 over the prior 109 months.

Below are key valuation metrics over time for RVNC.

Stock Date P/S P/B P/E EV/EBIT
RVNC 2023-01-20 24.0 17.9 -9.5 -11.3
RVNC 2023-01-19 22.1 16.5 -8.8 -10.5
RVNC 2023-01-18 22.2 16.6 -8.8 -10.6
RVNC 2023-01-17 21.2 15.8 -8.4 -10.1
RVNC 2023-01-13 21.2 15.8 -8.4 -10.1
RVNC 2023-01-12 20.1 15.0 -8.0 -9.7

RVNC Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at -111.26%.
  • Its 3 year revenue growth rate is now at 2254.05%.
  • The year over year net cashflow from operations growth rate now stands at 0.91%.
RVNC's revenue has moved up $108,294,000 over the prior 67 months.

The table below shows RVNC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 108.594 -207.977 -273.568
2022-06-30 99.324 -203.273 -263.251
2022-03-31 89.76 -208.053 -274.013
2021-12-31 77.798 -221.538 -281.31
2021-09-30 62.981 -239.241 -296.521
2021-06-30 47.071 -241.76 -303.402

RVNC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RVNC has a Quality Grade of D, ranking ahead of 5.83% of graded US stocks.
  • RVNC's asset turnover comes in at 0.068 -- ranking 297th of 681 Pharmaceutical Products stocks.
  • HGEN, ZSAN, and ARMP are the stocks whose asset turnover ratios are most correlated with RVNC.

The table below shows RVNC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.068 0.694 -0.733
2021-03-31 0.043 0.685 -0.794
2020-12-31 0.024 0.689 -0.784
2020-09-30 0.008 0.742 -0.784
2020-06-30 0.001 0.957 -0.721
2020-03-31 0.001 1.000 -0.749

RVNC Price Target

For more insight on analysts targets of RVNC, see our RVNC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $39.78 Average Broker Recommendation 1.35 (Strong Buy)

RVNC Stock Price Chart Interactive Chart >

Price chart for RVNC

RVNC Price/Volume Stats

Current price $33.13 52-week high $34.55
Prev. close $33.88 52-week low $11.27
Day low $32.88 Volume 728,800
Day high $33.98 Avg. volume 2,330,433
50-day MA $23.58 Dividend yield N/A
200-day MA $20.27 Market Cap 2.73B

Revance Therapeutics, Inc. (RVNC) Company Bio


Revance Therapeutics is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company was founded in 1999 and is based in Newark, California.


RVNC Latest News Stream


Event/Time News Detail
Loading, please wait...

RVNC Latest Social Stream


Loading social stream, please wait...

View Full RVNC Social Stream

Latest RVNC News From Around the Web

Below are the latest news stories about REVANCE THERAPEUTICS INC that investors may wish to consider to help them evaluate RVNC as an investment opportunity.

Revance Therapeutics, Inc. (RVNC) Soars 8.6%: Is Further Upside Left in the Stock?

Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Yahoo | January 23, 2023

Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results

NASHVILLE, Tenn., January 09, 2023--Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results

Yahoo | January 9, 2023

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

NASHVILLE, Tenn., January 06, 2023--Revance Announces U.S. FDA Acceptance of sBLA for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Yahoo | January 6, 2023

Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference

NASHVILLE, Tenn., November 22, 2022--Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference

Yahoo | November 22, 2022

Nanostics Announces New Member of Board of Directors

Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin will join the board of directors at Nanostics replacing Mr. Reg Joseph as one of the independent directors for the company.

Yahoo | November 17, 2022

Read More 'RVNC' Stories Here

RVNC Price Returns

1-mo 77.93%
3-mo 47.64%
6-mo 111.56%
1-year 163.98%
3-year 44.04%
5-year -2.84%
YTD 79.47%
2022 13.11%
2021 -42.41%
2020 74.61%
2019 -19.37%
2018 -43.69%

Continue Researching RVNC

Here are a few links from around the web to help you further your research on Revance Therapeutics Inc's stock as an investment opportunity:

Revance Therapeutics Inc (RVNC) Stock Price | Nasdaq
Revance Therapeutics Inc (RVNC) Stock Quote, History and News - Yahoo Finance
Revance Therapeutics Inc (RVNC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8027 seconds.